Clinical Improvement

PYRIDOSTIGMINE BROMIDE tablet [American Health Packaging] | National Institutes of Health | 11/9/2020

WARNINGS Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of pyridostigmine bromide may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by …

** | 11/4/2020**

… 2020. Of particular note are primary and key secondary endpoint data from additional analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in VOC. These findings point to the potential benefits, clinical improvement s and improved outcomes associated with early treatment with GlycoMimetics‚Äô wholly-owned product candidate, which include shorter hospital stays for patients and reduced need for IV opioids to treat pain. A second presentation includes …

GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition | Business & Finance | heraldchronicle.com | Business Wire | 11/4/2020

… 2020. Of particular note are primary and key secondary endpoint data from additional analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in VOC. These findings point to the potential benefits, clinical improvement s and improved outcomes associated with early treatment with GlycoMimetics‚Äô wholly-owned product candidate, which include shorter hospital stays for patients and reduced need for IV opioids to treat pain. A second presentation includes …

GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition | BioSpace | 11/4/2020

Of particular note are primary and key secondary endpoint data from additional analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in VOC. These findings point to the potential benefits, clinical improvement s and improved outcomes associated with early treatment with GlycoMimetics‚Äô wholly-owned product candidate, which include shorter hospital stays for patients and reduced need for IV opioids to treat pain. A second presentation includes data …

DSW Alumna Publishes Innovative Palliative Care Study | 11/2/2020

… hospice care, Gregory endeavors to identify solutions to hospice-at-home family caregiver stress and depression through her research. ‚ÄúWe found that the intervention significantly improved caregiver quality of life scores, and showed a clinical improvement in the positive problem orientation and rational problem-solving subscale scores for the intervention condition as compared to the control condition. We also concluded that brief problem-solving therapy delivered by a hospice social …

MESTINON (pyridostigmine bromide) solution MESTINON (pyridostigmine bromide) tablet MESTINON (pyridostigmine bromide) tablet, extended release [Bausch Health US, LLC] | National Institutes of Health | 10/29/2020

WARNINGS: Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of MESTINON may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme …

GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome - GuruFocus.com | 10/26/2020

… observed in all five treated patients across the key domains of communication, fine and gross motor skills, behavior, and sleep as measured by the CGI-I-AS. In some patients these initial indications of clinical improvement were observed by the investigator early in the study at the two lowest dose levels and began within weeks of the first dose. At day 128, all patients had a meaningful improvement in their …

Arches National Park, ski resorts, Amtrak: News from around our 50 states | 10/20/2020

… Laura Enos, acting director of public health nursing and leader of Whiteriver Indian Hospital’s contact tracing team. The visits typically continue until a high-risk patient is out of isolation or has “displayed notable clinical improvement s” for two days straight, she said. Arkansas Little Rock: A scaled-back version of the Arkansas State Fair, without crowds, rides and concerts, was held last weekend as the event’s size was significantly reduced …

PREDNISONE tablet [Proficient Rx LP] | National Institutes of Health | 10/19/2020

… and as to whether daily or intermittent therapy should be used. Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement . Cardio-Renal As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency …

Author Post: 5 Core Beliefs Blocking Digital Transformation In Health Systems | Forbes | 10/19/2020

… with over 100 of the country’s largest health systems and conversations with dozens more, we have uncovered five core beliefs that currently prevent many health systems from rapidly innovating and achieving significant operational and clinical improvement . Here are the five core beliefs and why they need to be overcome for a successful transformation:

  1. “Our EHR can do it all.” EHRs are good at a lot of things but predicting …

CO2 Laser Division of Neo-Vallecula Improves Dysphagia in the Postlaryngectomy Patient: A Case Series and Review of the Literature | 10/19/2020

… The patient lected to undergo pharyngoscopy and CO 2 laser diverticulectomy of his neo-vallecula. The diverticulectomy was conservative due to concern for pharyngocutaneous fistula formation. During initial follow-up, the patient noted some clinical improvement s and was able to swallow liquids but remained unable to pass a pill through his neopharyngeal inlet. A second CO 2 laser diverticulectomy was performed to remove the residual obstructing tissue, resulting in significant …

Transcatheter device may benefit patients with HF waiting for transplantation | 10/19/2020

A transcatheter device was a safe and effective bridge strategy to heart transplantation in patients with end-stage HF, with 23.5% removed from the list due to clinical improvement , researchers found in the MitraBridge registry. Cosmo Godino “In this scenario, the MitraClip (Abbott) can be utilized as a possible solution as a bridging strategy to heart transplantation in order to reduce worsening and progression of the underlying heart failure disease …

TCT Connect 2020: SOLVE-TAVI shows higher rate of stroke for balloon-expandable valve | 10/17/2020

… decade transcatheter aortic valve implantation (TAVI) has developed as the standard strategy in patients with severe symptomatic aortic stenosis at high to intermediate risk. “Major innovations in TAVI design led to relevant technical and clinical improvement s, for instance lower pacemaker rates, improved paravalvular regurgitation and also vascular complications,” he said. “Nevertheless there is limited data derived from randomised trials regarding direct valve comparisons.“ He added that regarding anaesthesia strategy, it …

Medicare Program; Town Hall Meeting on the FY 2022 Applications for New Medical Services and Technologies Add-On Payments | 10/16/2020

… than as an in-person meeting. Interested parties are invited to this meeting to present their comments, recommendations, and data regarding whether the FY 2022 new medical services and technologies applications meet the substantial clinical improvement criterion. DATES: Meeting Date(s): The Town Hall Meeting announced in this notice will be held virtually on Tuesday, December 15, 2020 and Wednesday, December 16, 2020 (the number of new technology applications submitted …

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion Brussels Stock Exchange:BOTHE | Globe Newswire | 10/14/2020

90% of patients show bone fusion as well as strong clinical improvement s in function and pain at 24 months follow-up period with a good product safety profile Gosselies, Belgium, 14 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces positive 24-month follow-up results for the Phase IIa study with the …

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion | Globe Newswire | 10/14/2020

90% of patients show bone fusion as well as strong clinical improvement s in function and pain at 24 months follow-up period with a good product safety profile Gosselies, Belgium, 14 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces positive 24-month follow-up results for the Phase IIa study with the …

Opinion: The placebo response: a hidden risk to Covid-19 trials | STAT | 10/13/2020

… response. It could contribute to clinical trial failures and delay the delivery of medications and vaccines to mitigate this global public health disaster. The placebo response is a complex psychobiological phenomenon that describes the clinical improvement seen in patients taking dummy or sham medicines. It can also comprise some proportion of the measured effect among patients receiving active drugs. Multiple behavioral, psychophysiological, and neuroimaging studies have shown that the placebo …

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement | BMJ | 10/12/2020

… to Dr Kimberly Showalter, Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA; showalterk(at)hss.edu Abstract Objective We sought to determine histologic and gene expression features of clinical improvement in early diffuse cutaneous systemic sclerosis (dcSSc; scleroderma). Methods Fifty-eight forearm biopsies were evaluated from 26 individuals with dcSSc in two clinical trials. Histologic/immunophenotypic assessments of global severity, alpha-smooth muscle actin …

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 | PR Newswire | 10/6/2020

… online, here . In this case report, Marcelo Gareca , MD, an Infectious Disease specialist at Lehigh Valley Hospital, Allentown, PA, provides details of a patient with severe COVID-19 and progressive hypoxia who demonstrated marked clinical improvement s following selinexor treatment without any reported adverse effects. XPO1 inhibitors, including selinexor, have demonstrated activity against over 20 different viruses, including the RNA viruses, influenza, respiratory syncytial virus (RSV) and other common causes of …

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 | BioSpace | 10/6/2020

… online, here . In this case report, Marcelo Gareca , MD, an Infectious Disease specialist at Lehigh Valley Hospital, Allentown, PA, provides details of a patient with severe COVID-19 and progressive hypoxia who demonstrated marked clinical improvement s following selinexor treatment without any reported adverse effects. XPO1 inhibitors, including selinexor, have demonstrated activity against over 20 different viruses, including the RNA viruses, influenza, respiratory syncytial virus (RSV) and other common causes of …

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 | 10/6/2020

… online, here . In this case report, Marcelo Gareca , MD, an Infectious Disease specialist at Lehigh Valley Hospital, Allentown, PA, provides details of a patient with severe COVID-19 and progressive hypoxia who demonstrated marked clinical improvement s following selinexor treatment without any reported adverse effects. XPO1 inhibitors, including selinexor, have demonstrated activity against over 20 different viruses, including the RNA viruses, influenza, respiratory syncytial virus (RSV) and other common causes of …

RELEASE — ACHP Chief Medical Officer Dr. Connie Hwang Appointed to PCORI Board of Governors | 10/5/2020

… efforts. “A brilliant and driven health care advocate, Dr. Hwang is an excellent addition to the Board of Governors,” said ACHP President & CEO Ceci Connolly. “In this role, she will continue to advance meaningful clinical improvement s and provide thoughtful, evidence-based guidance on the advancement of PCORI’s essential work.” PCORI is an independent, nonprofit organization authorized by Congress in 2010 to fund research that provides patients, their caregivers and clinicians …

Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis | 9/29/2020

Total for noninvasive group: 6 (12·5%) Bold values significance P  = .442 vs. invasive group. By post‐tocilizumab day 14, 28.8% of all patients had clinical improvement ; 19.7% had either no change, or only a modest improvement in their oxygenation support; 16.7% required advancement of oxygen support; and 27% died. In the invasive ventilation group, 16.7% had clinical improvement , compared with 33.3% of patients in the noninvasive oxygen support group …

NeuroRx Submits Request for Emergency Use Authorization for RLF-100™ (aviptadil) in the Treatment of Patients with Critical COVID-19 and Respiratory Failure Who Have Exhausted Approved Therapy | 9/23/2020

… treatment (n=30) in the same ICU by the same medical staff. Patients treated with RLF-100™ demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement . Hypotension was seen in two aviptadil patients and was successfully managed with pressors. Diarrhea was seen in 4/21 aviptadil-treated patients and 3/30 control patients. The results have been submitted to a peer-reviewed …

Roche’s Actemra helps keep coronavirus patients off ventilators despite earlier trial flop | FiercePharma | 9/18/2020

… for Actemra at 20 days, versus 28 days for placebo. But Actemra failed to top placebo in terms of clinical status improvement after four weeks—the trial’s primary endpoint—even though the likelihood of clinical improvement was slightly higher for the Roche drug. Similarly, in the current Empacta trial, it took Actemra a median of six days to help patients improve on the ordinal clinical status scale, while placebo patients …

Coronavirus

Arches National Park, ski resorts, Amtrak: News from around our 50 states | 10/20/2020

… Amtrak: News from around our 50 states Alabama Montgomery: Alabama’s monthly unemployment rate jumped to 6.6% in September as the coronavirus pandemic kept up its continuing damage to the state’s economy, the government reported Friday … risk patient is out of isolation or has “displayed notable clinical improvements” for two days straight, she said. Arkansas Little Rock: A scaled-back version of the Arkansas State Fair, without crowds, rides and concerts …

Smoking Cessation

PREDNISONE tablet [Proficient Rx LP] | National Institutes of Health | 10/19/2020

… been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement. Cardio-Renal As sodium retention with resultant edema and potassium loss may occur … Lifestyle modification to reduce the risk of osteoporosis (e.g., cigarette smoking cessation, limitation of alcohol consumption, participation in weight-bearing exercise for 30 to 60 minutes daily) should be encouraged. Calcium and vitamin D supplementation …

Medicare

Medicare Program; Town Hall Meeting on the FY 2022 Applications for New Medical Services and Technologies Add-On Payments | 10/16/2020

… present their comments, recommendations, and data regarding whether the FY 2022 new medical services and technologies applications meet the substantial clinical improvement criterion. DATES: Meeting Date(s): The Town Hall Meeting announced in this notice … on the New Technology website when available at: http://www.cms.gov/​Medicare/​Medicare-Fee-for-Service-Payment/​AcuteInpatientPPS/​newtech.html . Continue to check the website for updates. Registration and Special Accommodations: Individuals wishing to present at the …

Clinical Data

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 | PR Newswire | 10/6/2020

… here . In this case report, Marcelo Gareca , MD, an Infectious Disease specialist at Lehigh Valley Hospital, Allentown, PA, provides details of a patient with severe COVID-19 and progressive hypoxia who demonstrated marked clinical improvements following selinexor treatment without any reported adverse effects. XPO1 inhibitors, including selinexor, have demonstrated activity against over 20 different viruses, including the RNA viruses, influenza, respiratory syncytial virus (RSV) and other common causes of respiratory …

Food and Drug Administration

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 | BioSpace | 10/6/2020

… 20mg of selinexor given orally three times a week for two weeks, a dosing level significantly lower than the U.S. Food and Drug Administration (FDA) approved dose of selinexor, marketed as XPOVIO®, to treat patients … with severe COVID-19 and progressive hypoxia who demonstrated marked clinical improvements following selinexor treatment without any reported adverse effects. XPO1 inhibitors, including selinexor, have demonstrated activity against over 20 different viruses, including the RNA …

COVID-19

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 | BioSpace | 10/6/2020

… at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group (ISIRV-AVG) Virtual Conference on Therapeutics for COVID-19 taking place from October 6 - 8, 2020 . The presentation will feature data from … with severe COVID-19 and progressive hypoxia who demonstrated marked clinical improvements following selinexor treatment without any reported adverse effects. XPO1 inhibitors, including selinexor, have demonstrated activity against over 20 different viruses, including the RNA …

National Institute of Allergy and Infectious Diseases

Researchers call out Gilead over diversity of remdesivir trials | FierceBiotech | 8/12/2020

… National Institute of Allergy and Infectious Diseases’ Adaptive Covid-19 Treatment Trial were Black—but still too low in the view of the researchers. “The modest benefit seen in time to clinical improvement with remdesivir may not be generalizable to minority populations, given the differences in disease severity and outcomes,” the authors wrote. A lack of diversity in clinical trials is a long-standing problem that has persisted despite federal …

Biopharma

RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK | Globe Newswire | 6/29/2020

… severe COVID-19 patients has been initiated at leading medical centers TEL-AVIV, Israel and RALEIGH, N.C., June 29, RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that … COVID-19 patients treated with opaganib will not show any clinical improvement; the risk that clinical trials of opaganib in Israel, the U.S., Italy, Russia, the UK or elsewhere for the treatment of COVID-19 …

Biotech

Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | PR Newswire | 6/17/2020

… drug companies, government laboratories and top universities — are working on a vaccine or other treatments, according to leading researchers.” Active biotech companies with recent developments include: Nascent Biotech, Inc. (OTCQB: NBIO ), Moderna, Inc. (NASDAQ: MRNA … remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement …

National Institutes of Health

A drug from Shkreli’s former company Humanigen shows early promise in COVID-19 | FierceBiotech | 6/17/2020

… with an FDA emergency authorization in COVID-19—as posted in a separate placebo-controlled clinical trial conducted by the National Institutes of Health. Encouraged by the early results, Humanigen has launched a phase 3 … investigational drug outside a clinical trial, lenzilumab led to rapid clinical improvement. Of the 12 patients who received lenzilumab, 11 were already discharged at the data cutoff date. The treatment also produced a significant improvement …

NIH

Eli Lilly, spurred by AI analysis, starts pivotal study of arthritis med Olumiant in COVID-19 | FiercePharma | 6/15/2020

… hospitalized patients, it said Monday. Data from the trial, expected in the next few months, will complement those from the NIH-run ACTT-2 trial, which is combining Olumiant with Gilead Sciences’ remdesivir. The drug … Olumiant and placebo. Investigators will also measure other outcomes, including clinical improvement, time to recovery and duration of hospitalization. Besides Olumiant, Lilly is working on two investigational neutralizing antibody drugs specifically designed to target the …

Institutional Review Board

OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19 | Business Wire | 6/14/2020

… randomized and received either CD24Fc or placebo as the treatment for severe COVID-19. After reviewing the safety data, the Institutional Review Board has approved continuing enrollment while interim analysis occurs. Current therapeutic strategies for … up for 28 days thereafter to determine the time to clinical improvement. Because the drug works through a novel mechanism that does not duplicate that of other experimental therapeutics, patients enrolled in other trials need …

Medicaid

VasQ™ External Support Awarded Breakthrough Device Designation by the FDA | PR Newswire | 6/8/2020

Medicaid Services as substantiation of clinical improvement in their consideration for providing additional reimbursement for new technologies. The designation was based in part on the breadth of clinical evidence collected so far for VasQ that consistently demonstrates improvement over the standard of care for creating functional AVFs for hemodialysis treatment. AVFs are the preferred option by physicians for hemodialysis patients to enable effective treatment because of their long-term benefits …

Centers for Medicare and Medicaid Services

VasQ™ External Support Awarded Breakthrough Device Designation by the FDA | PR Newswire | 6/8/2020

Centers for Medicare and Medicaid Services as substantiation of clinical improvement in their consideration for providing additional reimbursement for new technologies. The designation was based in part on the breadth of clinical evidence collected so far for VasQ that consistently demonstrates improvement over the standard of care for creating functional AVFs for hemodialysis treatment. AVFs are the preferred option by physicians for hemodialysis patients to enable effective treatment because of …

Genomics

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology | Globe Newswire | 5/26/2020

… this rare condition,” said George Diaz, M.D., Ph.D., division chief of medical genetics in the Division of Medical Genetics and Genomics and Department of Genetics and Genomic Sciences at the Icahn School of Medicine at … extension data for pegzilarginase in patients with ARG1-D demonstrated clinical improvements and sustained lowering of plasma arginine. The Company’s single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment …

Home Health

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home | PR Newswire | 5/4/2020

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home News provided by May 04, 2020, 08:39 ET Share this article … a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, COPD and hypertension, resulting in reductions in hospital admissions, and solid financial return on investment. For more …

CDC

AbbVie’s HIV drug fails Covid-19 trial in China, but a Fujifilm flu drug may have efficacy - MedCity News | 3/20/2020

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses Researchers in China testing drugs as potential treatments for Covid-19 racked up one failure and one … from the standard of care in terms of time to clinical improvement. Thirteen patients receiving the drug dropped out due to adverse events, but although gastrointestinal side effects were higher in the Kaletra group, serious …

Patient Satisfaction

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

… clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is, it’s never about one of these — it’s about all of them, or some combination thereof, so you need to know what you want to measure and what the data source is, and bring that information from multiple places to save money and time,” Dr. Blackman said. 2. Identify needs: With a strategy fully defined and …

Telehealth

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

… first and most important step is deploying and defining a strategy: determining whether the goals of the software lie in clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is … in care, think beyond the in-person visit to encompass telehealth and other virtual solutions, address the patients not currently being seen, and feature a robust analytics strategy to create insights and enable action. “A …

Population Health

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

In the U.S. the push for population health management is largely driven by rising healthcare costs and rates of chronic illness. Costs are growing at an unsustainable rate and do not correspond with care quality … strategy: determining whether the goals of the software lie in clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is, it’s never about one of these — it’s about all of …

Health Management

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

In the U.S. the push for population health management is largely driven by rising healthcare costs and rates of chronic illness. Costs are growing at an unsustainable rate and do not correspond with care quality … strategy: determining whether the goals of the software lie in clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is, it’s never about one of these — it’s about all of …

Clinical Pharmacology

METHOTREXATE injection, solution [Teva Parenteral Medicines, Inc.] | National Institutes of Health | 12/3/2019

… mL solutions contain approximately 0.43 mEq, 2.15 mEq and 8.60 mEq of sodium per vial, respectively, and are isotonic solutions. CLINICAL PHARMACOLOGY Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this … Limited data from long-term studies indicate that an initial clinical improvement is maintained for at least two years with continued therapy. In psoriasis, the rate of production of epithelial cells in the skin is …

Gene Therapy

UMass Med School gene therapy shows promising early results in tackling Tay-Sachs - News - telegram.com - Worcester, MA | 11/28/2019

UMass Med School gene therapy shows promising early results in tackling Tay-Sachs Susan Spencer Telegram & Gazette Staff @SusanSpencerTG Wednesday Nov 27, 2019 at 6:11 PM Nov 27, 2019 at 6:37 PM WORCESTER — The fight … injected into fluid surrounding the brain. The patient hasn’t shown clinical improvement in functioning but biochemical changes were detected in the brain, indicating partial re-creation of the missing enzyme associated with Tay-Sachs, Flotte …

Patient Safety

(USA-MA-Boston) Director, Patient Safety | 11/27/2019

Job Information Dana-Farber Cancer Institute Director, Patient Safety in Boston , Massachusetts The Director of patient Safety is responsible leading, evaluating, and implementing patient safety and clinical improvement initiatives across the Dana-Farber Cancer Institute (DFCI) continuum. The incumbent is responsible for Infection Control in collaboration with the Hospital Epidemiologist across DFCI. The [job title] is responsible for ensuring visibility of patient safety programs across DFCI and leading a non …

Clinical Decision Support

GE Healthcare introduces Edison Developer Program to spur AI advancements | Healthcare IT News | 11/27/2019

… for its Edison platform, the program will offer services meant to help developers to build better models for operational and clinical improvements. November 27, 2019 02:04 PM With its new Edison Developer Program, GE Healthcare … and Volpara – aimed at imaging workflows for CTs and MRIs, clinical decision support and more. Officials say the Edison Developer Program offers new potentials for innovating secure device connectivity, data aggregation for clinical context, advanced …

GlaxoSmithKline

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement | BMJ | 10/12/2020

… New York, NY 10021, USA; showalterk(at)hss.edu Abstract Objective We sought to determine histologic and gene expression features of clinical improvement in early diffuse cutaneous systemic sclerosis (dcSSc; scleroderma). Methods Fifty-eight forearm biopsies … investigator-initiated studies supported by research grants from Novartis and GlaxoSmithKline, respectively. Competing interests RSpiera reports receiving funds for the following activities: Research support: GlaxoSmithKline, Genentech/Roche, Novartis, Corbus Pharmaceuticals, Cytori Therapeutics, Evidera, Actelion Pharmaceuticals …

Gilead Sciences

Roche’s Actemra helps keep coronavirus patients off ventilators despite earlier trial flop | FiercePharma | 9/18/2020

… top placebo in terms of clinical status improvement after four weeks—the trial’s primary endpoint—even though the likelihood of clinical improvement was slightly higher for the Roche drug. Similarly, in the current Empacta trial … the death rate. Meanwhile, Roche is also pairing Actemra with Gilead Sciences’ antiviral Veklury, better known as remdesivir, in the phase 3 Remdacta trial. Eli Lilly’s JAK arthritis med Olumiant combined with Veklury helped patients …

Gilead

Researchers call out Gilead over diversity of remdesivir trials | FierceBiotech | 8/12/2020

… have called for sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an analysis of Gilead’s remdesivir clinical trials that found the studies “failed to provide equal representation of Black … of the researchers. “The modest benefit seen in time to clinical improvement with remdesivir may not be generalizable to minority populations, given the differences in disease severity and outcomes,” the authors wrote. A lack of …

Novartis

Coronavirus tracker: U.S. calls dibs on remdesivir supplies; Sinopharm doubles shot capacity with new Wuhan plant | FiercePharma | 7/1/2020

… called dibs on the its next 500,000 doses, shutting out other countries for at least the next three months. Plus, Novartis CEO Vas Narasimhan sat down with Wired to talk vaccines, pricing and drug launches … of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said. Story Could COVID-19 be a vascular disease? The Lancet explored the idea …

Incyte

Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients | Globe Newswire | 6/18/2020

… randomized, double-blind, placebo‑controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with COVID-19. Baricitinib, marketed as OLUMIANT ® , is approved in 70 … outcomes of this study include the proportion of patients with clinical improvement at different time points, time to recovery, duration of hospitalization, number of ventilator-free days and mortality over a 28-day period. “Lilly …

Johnson & Johnson

Ankylosing Spondylitis Market Size Worth $7.9 Billion By 2027 | CAGR: 8.3%: Grand View Research, Inc. | PR Newswire | 6/18/2020

… Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017 , Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active … approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs. Grand View Research has segmented the global ankylosing …

Inovio Pharmaceuticals

Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | PR Newswire | 6/17/2020

… biotech companies with recent developments include: Nascent Biotech, Inc. (OTCQB: NBIO ), Moderna, Inc. (NASDAQ: MRNA ), Gilead Sciences, Inc. (NASDAQ: GILD ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Eli Lilly and Company (NYSE: LLY ). The LA Time article … remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement …

Eli Lilly

Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | PR Newswire | 6/17/2020

… include: Nascent Biotech, Inc. (OTCQB: NBIO ), Moderna, Inc. (NASDAQ: MRNA ), Gilead Sciences, Inc. (NASDAQ: GILD ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Eli Lilly and Company (NYSE: LLY ). The LA Time article continued : “No response has ever … remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement …

AstraZeneca

Dr. Reddy’s Inks Deal With Gilead Sciences for Remdesivir - June 15, 2020 - Zacks.com | 6/15/2020

clinical improvement at day 11 compared with those in the standard of care group. However, the odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care alone were favorable but did not attain statistical significance. Meanwhile, several marketed drugs like Sanofi,/Regeneron’s IL-6 inhibitor Kevzara, Roche’s ( RHHBY - Free Report ) IL-6 inhibitor, Actemra, Incyte/Novarts’ JAK1/JAK2 inhibitor, Jakafi, AstraZeneca’s ( AZN …

Genentech

Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia | Business Wire | 5/28/2020

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–May 28, 2020– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the initiation of a global Phase III, randomized, double-blind, multicenter study … mortality, mechanical ventilation, clinical status at day 14, time to clinical improvement, and time to discharge. About Actemra Actemra was the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult …

AMC Health

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home | PR Newswire | 5/4/2020

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home News provided by May 04, 2020, 08:39 ET Share this article … a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, COPD and hypertension, resulting in reductions in hospital admissions, and solid financial return on investment. For more …

BioCryst

BioCryst Begins Study on Galidesivir for Coronavirus Infection - April 13, 2020 - Zacks.com | 4/13/2020

BioCryst Pharmaceuticals, Inc. ( BCRX - Free Report ) announced that it has initiated enrollment in a clinical study on its pipeline candidate galidesivir for treating patients with the novel coronavirus disease (COVID-19). The double-blind, placebo … the COVID-19 study will include the time taken to clinical improvement, time to hospital discharge, time to undetectable levels as measured by polymerase chain reaction (PCR) in respiratory specimens of SARS-CoV-2. Per …

AbbVie

FiercePharmaAsia—Biogen’s, Bayer’s rogue employees; Kaletra’s COVID-19 trial flop; BioNTech-Fosun deal | 3/20/2020

… a 14-day quarantine rule in China after videos of the woman’s behavior went viral. A Chinese research team found AbbVie’s HIV combo Kaletra offered no benefits over standard care in severe COVID-19 patients … failed to beat standard care at cutting the time to clinical improvement and the 28-day mortality rate. One analyst argues the med might be more helpful in less severe patients, though. 4. With weeks …

Boston Scientific

Bioresorbable scaffold effectively treats below-the-knee lesions | 11/14/2019

… below-the-knee lesions, the patency rate was 11.6%, he said. In addition, he said, 95% of patients showed sustained clinical improvement at 35 months, dropping in Rutherford class. The study included 48 patients (mean … Disclosure s : Kum reports he has financial ties with Abbott, Boston Scientific and LimFlow. Varcoe reports he consulted for and/or received honoraria from Abbott Vascular, Boston Scientific, Intact Vascular, Medtronic, Shockwave Medical and Surmodics …

Enable Healthcare

Leading Expert in Internal Medicine and Diabetes, Dr. Gregory Peterson, Joins AMC Health’s Clinical Leadership Team as Chief Medical Director to Enhance Remote Patient Monitoring (RPM) Solutions | PR Newswire | 10/30/2019

enable healthcare organizations to securely extend their services beyond the four walls of the hospital and ambulatory clinic settings. Providing cost-effective population health management, the company’s ever-expanding ecosystem delivers scalable virtual care programs for health systems and payers, connecting to more than 200 devices, apps, and integrations via a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, and hypertension …

Zynx Health

(USA-CA-Los Angeles) Account Executive | 10/27/2019

… ZYNX HEALTH Zynx Health, a subsidiary of Hearst Corporation, is the market leader in providing evidence-based and experience-based clinical decision support solutions proven to measurably improve the quality, safety, and efficiency of patient care. Zynx Health provides clinical evidence, order sets, plans of care, actionable rules, and other forms of clinical decision support that drive clinical improvements at the point of care and aligns with healthcare industry drivers …

MedHOK

With Quality a Top Priority, Ardent Health Services Expands Its Use of Zynx Health’s Knowledge Analyzer | PR Newswire | 7/9/2019

LOS ANGELES Zynx Health ™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today that long-time client Ardent Health Services is expanding its agreement for use of Zynx’s Knowledge … FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures ( www.hearsthealth.com ). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen …

GSK

Glaxo’s Dovato Wins EU Nod, RA Candidate Enters Phase III - July 4, 2019 - Zacks.com | 7/4/2019

GlaxoSmithKline plc ’s ( GSK - Free Report ) HIV subsidiary, ViiV Healthcare, announced that the European Commission has granted a marketing authorization to Dovato, its once-daily, single-tablet two-drug HIV regimen. The approval in the … data from the phase II BAROQUE study, which showed striking clinical improvements in patients treated with otilimab. Zacks Rank Glaxo currently carries a Zacks Rank 3 (Hold). You can see the complete list of today’s …

Celgene

–Fedratinib demonstrated clinical improvement in | 1/8/2018

Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naive myelofibrosis patients and in a phase II trial with myelofibrosis patients resistant or intolerant to ruxolitinib \n –A New Drug Application (NDA) submission for fedratinib in myelofibrosis is planned for mid-2018 \n Celgene Corporation ( NASDAQ:CELG ) and Impact Biomedicines today \n announced the signing of a definitive agreement in which Celgene will \n acquire Impact Biomedicines, which …

Morgan Stanley

Edited Transcript of INSM earnings conference call or presentation 30-Apr-20 12:30pm GMT | Yahoo News | 6/6/2020

… CEO & Chairman Conference Call Participants Adam Anderson Walsh Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Analyst Connor McGuinness Meehan Morgan Stanley, Research Division - Research Associate Graig Suvannavejh Goldman Sachs Group Inc., Research Division - Executive … on top of standard of care. The primary endpoint is clinical improvement on a 7-point ordinal scale as defined by the World Health Organization. Patients will be treated for up to 28 days with …

Live updates on COVID-19: April 1-15 | Modern Healthcare | 5/5/2020

… every shift. Several local news outlets also believe some states are undercounting the number of people succumbing to the disease. Morgan Stanley’s estimates on outbreak recovery Morgan Stanley: “While we understand the desire for optimism … remdesivir on patients hospitalized for severe COVID-19 resulted in clinical improvement 36 of 53, or 68%, of patients, according to an article in the New England Journal of Medicine. The Gilead Sciences-funded trial …

Goldman Sachs

Edited Transcript of INSM earnings conference call or presentation 30-Apr-20 12:30pm GMT | Yahoo News | 6/6/2020

… Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Analyst Connor McGuinness Meehan Morgan Stanley, Research Division - Research Associate Graig Suvannavejh Goldman Sachs Group Inc., Research Division - Executive Director & Senior Equity Research Analyst Joseph Patrick Schwartz … on top of standard of care. The primary endpoint is clinical improvement on a 7-point ordinal scale as defined by the World Health Organization. Patients will be treated for up to 28 days with …

Atara Biotherapeutics’ (ATRA) CEO Pascal Touchon on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/9/2019

… Rama – JPMorgan John Newman – Canaccord Salim Syed – Mizuho Securities Phil Nadeau – Cowen and Company Tony Butler – Roth Capital Salveen Richter – Goldman Sachs Ben Burnett – Stifel Maury Raycroft – Jefferies Operator Ladies and gentlemen, thank you for … tolerated safety profile and at least 50% of patients experiencing clinical improvement based on the multi-scale assessment defined at ECTRIMS with improving patient coming from more than one clinical study site. Recognizing these are …

Merrill Lynch

Shockwave Medical Inc (SWAV) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/11/2019

… Ordinarily when a medical device is being assessed for an add-on payment CMS looks at 3 criteria: newness substantial clinical improvement to alternative treatments and costs. However ,for a device that has been granted … Robert Hopkins with Bank of America. Kyle Andrew Pezzi – BofA Merrill Lynch – Analsyt This is Kyle Pezzi on for Bob. Just a quick question to kind of follow up to David. Obviously earlier this month …

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/15/2019

… ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder and CEO Conference Call Participants Ying Huang - Bank of America/Merrill Lynch Joseph Schwartz - SVB Leerink Josh Schimmer - Evercore Operator Good morning, and welcome to … the induction timeframe of where we can start seeing some clinical improvement. So a lot of data will be coming out of that Phase 1b trial. So again pretty exciting studies from our perspective and …

William Blair

CELYAD SA/ADR’s (CYAD) Buy Rating Reiterated at William Blair - Ticker Report | 8/26/2019

William Blair reaffirmed their buy rating on shares of CELYAD SA/ADR (NASDAQ:CYAD) in a research note published on Friday, AnalystRatings.com reports. “We believe that the data readouts in the second half of the year will shed light into the clinical improvements with the Optimab process, allogeneic platform, and the impact of the preconditioning regimen at potentially clinically relevant doses with an eye toward selecting a Phase II (potentially …

Premier, Inc. (PINC) CEO Susan DeVore on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/12/2019

… Alkire - President & COO Craig McKasson - CFO, CAO, Senior VP & Treasurer Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair Stephanie Demko - Citi Sean Dodge - Jefferies Kevin Caliendo - UBS Charles Rhyee - Cowen Sean … and leverage enterprise analytics to drive improved financial, operational and clinical improvement. In addition, we’re encouraged by recent federal government health policy announcements, as Premier continues to lead and support health systems in their transition …

Hearst Health Ventures

With Quality a Top Priority, Ardent Health Services Expands Its Use of Zynx Health’s Knowledge Analyzer | PR Newswire | 7/9/2019

LOS ANGELES Zynx Health ™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today that long-time client Ardent Health Services is expanding its agreement for use of Zynx’s Knowledge … Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures ( www.hearsthealth.com ). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth …

Zynx Health to Host Webinar: “Zynx FHIR API: Your Shortcut to App Excellence” | PR Newswire | 11/2/2017

… by 08:04 ET Share this article LOS ANGELES , Nov. Zynx Health ™, a market leader in providing evidence- and experience-based clinical improvement solutions, today announced it will host a live, complimentary webinar entitled, “ Zynx FHIR … Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health International, Hearst Health Ventures and the Hearst Health Innovation Lab ( www.hearsthealth.com ). The mission of the Hearst Health network is to help guide the most important care …

Northwell Health

Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus | BMJ | 6/8/2020

Table 3 NYP/CUMC and Northwell Health adult inpatients with PML codes One Northwell Health patient with ICD codes for both SLE and PML had a presentation consistent with CNS lupus and not PML with CSF negative for JC virus, and clinical improvement with increased immunosuppression. Of 2046 patients, 979 were being treated with glucocorticoids, 260 with mycophenolate mofetil, 85 with intravenous cyclophosphamide, 40 with rituximab, 70 with azathioprine, 616 …

Northwell memo calls for rationing ventilators to ‘patients most likely to benefit’ | Politico | 4/3/2020

Northwell Health wrote in a six-page memo titled “Public Health Emergency: Life Sustaining Treatment Decisions for all Patients” and distributed to medical staff. Advertisement The guidance, which was obtained by POLITICO, recommends that medical teams reevaluate patients with advanced illnesses who are breathing through a ventilator for three days if they show no “no clinical improvement.” At that point, the team should consult palliative care specialists to discuss whether …

Harvard Medical School

Biologics Alliance™ Initiates Collaboration Within Orthopaedics Community | PR Newswire | 11/25/2019

… into question the ability of treatments such as oral medications, injection therapies, physical therapy, arthroscopy and arthroplasty to provide significant clinical improvement to patients with osteoarthritis (OA), the most common condition evaluated and treated by … Director, Cartilage Repair Center at Brigham and Women’s Hospital at Harvard Medical School Bert Mandelbaum , M.D., (Co-Chair of the Alliance) , Co-Chair, Medical Affairs Cedars Sinai Kerlan Jobe Institute, Co-Director, Sports Medicine Cedars …

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform | Business Wire | 11/21/2019

… Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School, Mario Suvà M.D., Ph.D ., an Associate Professor in the Department of Pathology … tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and …

Patrik Jonsson

Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients | PR Newswire | 6/15/2020

clinical improvement at different time points, time to recovery, duration of hospitalization, number of ventilator-free days and mortality over a 28-day period. “Lilly is committed to fighting this global pandemic, and this includes testing whether existing medicines including baricitinib could help treat the complications of COVID-19 in patients,” said Patrik Jonsson , Lilly senior vice president and president of Lilly Bio-Medicines. “This randomized controlled study is an …

Anthony Fauci

Remdesivir in the plague year: “Observations of the most remarkable occurences” | BMJ | 6/10/2020

… associated with statistically significant clinical benefits in the treatment of severe covid-19. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.” [ 2] On the same … AP News proclaimed the results “A 1 st ” and quoted Anthony Fauci of the National Institutes of Health saying that “What it has proven is that a drug can block this virus,” that “This will …

Merdad Parsey

More evidence remdesivir helps some coronavirus patients | Philly Tribune | 6/3/2020

… today, we now have three randomized, controlled clinical trials demonstrating that remdesivir improved clinical outcomes by several different measures,” Dr. Merdad Parsey, chief medical officer for Gilead Sciences, said in a company statement . Gilead originally … five-day course of remdesivir were more likely to have clinical improvement after 11 days compared to those who received traditional standard of care alone, Gilead said. However, while patients who received a 10-day …

Deena Beasley

Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one | Yahoo News | 5/29/2020

FILE PHOTO: A vial of redesivir More By Deena Beasley (Reuters) - Gilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of … 5 days and 54% treated for 10 days showed some clinical improvement. At the 14-day mark, 8% of patients in the 5-day group and 11% of patients in the 10-day group had …

Levi Garraway

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia | Globe Newswire | 5/28/2020

… becomes available in these unprecedented times, it is more important than ever to work together to fight this disease,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Based … mortality, mechanical ventilation, clinical status at day 14, time to clinical improvement, and time to discharge. About Actemra/RoActemra Actemra/RoActemra was the first approved anti-IL-6 receptor biologic available in both intravenous (IV …

Nesim Bildirici

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home | PR Newswire | 5/4/2020

… one-size-fits-all approach – it’s about meeting the needs of our clients when and where they want it,” said Nesim Bildirici , CEO of AMC Health. AMC’s telehealth capabilities serve hospitals, health plans, and Veterans … a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, COPD and hypertension, resulting in reductions in hospital admissions, and solid financial return on investment. For more …

Matthew Herper

Gilead: Critical study of Covid-19 drug shows patients respond to treatment | STAT | 4/29/2020

Biotech Critical study of Gilead’s Covid-19 drug shows patients are responding to treatment, NIH says By Matthew Herper @matthewherper and Adam Feuerstein @adamfeuerstein April 29, 2020 A vial of remdesivir ULRICH PERREY/POOL/AFP … with severe Covid-19. This study showed similar rates of clinical improvement in patients treated with a five-day and 10-day course of remdesivir, the company said. “Unlike traditional drug development, we are attempting …

Adam Feuerstein

Gilead: Critical study of Covid-19 drug shows patients respond to treatment | STAT | 4/29/2020

… Critical study of Gilead’s Covid-19 drug shows patients are responding to treatment, NIH says By Matthew Herper @matthewherper and Adam Feuerstein @adamfeuerstein April 29, 2020 A vial of remdesivir ULRICH PERREY/POOL/AFP via … with severe Covid-19. This study showed similar rates of clinical improvement in patients treated with a five-day and 10-day course of remdesivir, the company said. “Unlike traditional drug development, we are attempting …

Andy Boral

Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis | PR Newswire | 3/16/2020

… announced updated results from the Phase 2 PIONEER trial of avapritinib in patients with indolent systemic mastocytosis (SM) showing significant clinical improvements versus placebo. In Part 1 of the PIONEER trial, patients treated with avapritinib … with the goal of delivering transformative benefit to patients,” said Andy Boral , M.D., Ph.D., Chief Medical Officer at Blueprint Medicines. “In indolent SM, these placebo-controlled data are the first to show consistent clinical activity …

Bruce Pat

CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140) | Globe Newswire | 3/9/2020

… as a therapy for patients who experience respiratory complications as a result of contracting the coronavirus disease 2019 (COVID-19). Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn explains: “Leronlimab inhibits migration of … in subjects with coronavirus 2019 infection. Primary Outcome (Endpoint) Measure: Clinical Improvement based on change in total symptom score (for fever, myalgia, dyspnea and cough)Note: The total score per patient ranges from 0 to …

Anupam Rama

Atara Biotherapeutics’ (ATRA) CEO Pascal Touchon on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/9/2019

… Investor Relations and Corporate Communications Pascal Touchon – President and Chief Executive Officer AJ Joshi – Chief Medical Officer Conference Call Participants Anupam Rama – JPMorgan John Newman – Canaccord Salim Syed – Mizuho Securities Phil Nadeau – Cowen and Company … tolerated safety profile and at least 50% of patients experiencing clinical improvement based on the multi-scale assessment defined at ECTRIMS with improving patient coming from more than one clinical study site. Recognizing these are …

Craig Fraser

Windtree Therapeutics Provides Business Update – Company Announcement - FT.com | Financial Times | 10/25/2019

… our data analysis, gained increased regulatory clarity and evolved our development strategies for the next stages of program execution,” commented Craig Fraser , President and Chief Executive Officer. “We are excited about the opportunities before us … dose group), suggesting that istaroxime could potentially contribute to the clinical improvement of patients in cardiogenic shock due to heart failure. Because of the unmet need, there may be opportunities for an enhanced regulatory pathway …

Adam Grossman

ADMA Biologics Named Company of the Year by BioFlorida | Globe Newswire | 10/22/2019

… BioFlorida and to be recognized for the recent achievements at our Boca Raton, Florida biologics manufacturing and laboratory campus,” stated Adam Grossman, President and Chief Executive Officer. “Over the past year, we were granted two … plasma-based biologics products and product candidates to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease or other indications. Actual events or results may differ materially from those described in this …

Chaim Lebovits

BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update | Globe Newswire | 5/11/2019

… our Phase 2 trial of NurOwn ® in Progressive MS (Multiple Sclerosis) in several of the preeminent U.S. medical institutions,” commented Chaim Lebovits, President and Chief Executive Officer of BrainStorm Cell Therapeutics. He added, “We anticipate … production by NurOwn ® and further correlate cerebrospinal fluid biomarkers with clinical improvement in the completed Phase 2 ALS study. These findings contribute to our overall understanding of the mechanism of action of NurOwn ® and provide …

David Evans

Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2 | Markets Insider | Business Insider | 5/9/2019

David Evans, Ph.D., Guardion’s Chief Science Officer, commenting on the results of the study, stated, “We are pleased to present for the first-time clinical data showing the beneficial effects of our liquid lipid-based formula Lumega-Z as compared to the AREDS 2 softgel supplement. This data supports numerous clinical reports that we have showing substantial clinical improvements in patients who switched from the AREDS 2 softgel to Lumega …

State of Washington

Arches National Park, ski resorts, Amtrak: News from around our 50 states | 10/20/2020

… rate and even worse when compared to the precoronavirus rate of 2.7% a year earlier. The state’s labor secretary, Fitzgerald Washington, said fluctuations in the unemployment rate will likely continue during the pandemic, which is … risk patient is out of isolation or has “displayed notable clinical improvements” for two days straight, she said. Arkansas Little Rock: A scaled-back version of the Arkansas State Fair, without crowds, rides and concerts …

RELEASE — ACHP Chief Medical Officer Dr. Connie Hwang Appointed to PCORI Board of Governors | 10/5/2020

Press Release RELEASE — ACHP Chief Medical Officer Dr. Connie Hwang Appointed to PCORI Board of Governors Washington, D.C. (October 5, 2020) – Alliance of Community Health Plans (ACHP) Chief Medical Officer and Director of Clinical Innovation … Connolly. “In this role, she will continue to advance meaningful clinical improvements and provide thoughtful, evidence-based guidance on the advancement of PCORI’s essential work.” PCORI is an independent, nonprofit organization authorized by Congress in …

New York, New York

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement | BMJ | 10/12/2020

… Dana E Orange 1 , 7 , Jessica K Gordon 1 1 Department of Medicine, Division of Rheumatology , Hospital for Special Surgery , New York , New York , USA 2 Department of Pathology and Laboratory Medicine , Weill Cornell Medicine … We sought to determine histologic and gene expression features of clinical improvement in early diffuse cutaneous systemic sclerosis (dcSSc; scleroderma). Methods Fifty-eight forearm biopsies were evaluated from 26 individuals with dcSSc in two clinical …

Satisfactory Progress Reports for MitraClip Alternatives | 6/25/2020

… mild in all implanted patients at 30 days (83.3% had no MR). Symptoms improved from 64.3% of patients being in New York Heart Association (NYHA) class III or worse at baseline to 81.8% left with … and 92.0% had grade 4+ MR. Muller highlighted the sustained clinical improvement observed in terms of NYHA classification (81.7% in class I/II at 2 years) and a 19-point improvement on the Kansas City …

York, Pennsylvania

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement | BMJ | 10/12/2020

… E Orange 1 , 7 , Jessica K Gordon 1 1 Department of Medicine, Division of Rheumatology , Hospital for Special Surgery , New York , New York , USA 2 Department of Pathology and Laboratory Medicine , Weill Cornell Medicine , New … We sought to determine histologic and gene expression features of clinical improvement in early diffuse cutaneous systemic sclerosis (dcSSc; scleroderma). Methods Fifty-eight forearm biopsies were evaluated from 26 individuals with dcSSc in two clinical …

Satisfactory Progress Reports for MitraClip Alternatives | 6/25/2020

… in all implanted patients at 30 days (83.3% had no MR). Symptoms improved from 64.3% of patients being in New York Heart Association (NYHA) class III or worse at baseline to 81.8% left with NYHA … and 92.0% had grade 4+ MR. Muller highlighted the sustained clinical improvement observed in terms of NYHA classification (81.7% in class I/II at 2 years) and a 19-point improvement on the Kansas City …

State of New York

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement | BMJ | 10/12/2020

… Dana E Orange 1 , 7 , Jessica K Gordon 1 1 Department of Medicine, Division of Rheumatology , Hospital for Special Surgery , New York , New York , USA 2 Department of Pathology and Laboratory Medicine , Weill Cornell Medicine … We sought to determine histologic and gene expression features of clinical improvement in early diffuse cutaneous systemic sclerosis (dcSSc; scleroderma). Methods Fifty-eight forearm biopsies were evaluated from 26 individuals with dcSSc in two clinical …

Satisfactory Progress Reports for MitraClip Alternatives | 6/25/2020

… mild in all implanted patients at 30 days (83.3% had no MR). Symptoms improved from 64.3% of patients being in New York Heart Association (NYHA) class III or worse at baseline to 81.8% left with … and 92.0% had grade 4+ MR. Muller highlighted the sustained clinical improvement observed in terms of NYHA classification (81.7% in class I/II at 2 years) and a 19-point improvement on the Kansas City …

Peoria, Illinois

Peoria hospitals receive shipments of Remdesivir, an experimental treatment for COVID-19 | 5/19/2020

PEORIA – Healthcare professionals in Peoria now have another weapon in their arsenal in the ongoing fight against COVID-19. “Over the weekend, UnityPoint Methodist received an allocation of Remdesivir, which is an antiviral medication which … to shorten the duration of illness, and has shown some clinical improvement,” said Sudhindra. “The trial that was published in the New England Journal of Medicine was still ongoing, but they said two-thirds of …

Peoria hospitals receive shipments of Remdesivir, an experimental treatment for COVID-19 | 5/19/2020

PEORIA – Healthcare professionals in Peoria now have another weapon in their arsenal in the ongoing fight against COVID-19. “Over the weekend, UnityPoint Methodist received an allocation of Remdesivir, which is an antiviral medication which … to shorten the duration of illness, and has shown some clinical improvement,” said Sudhindra. “The trial that was published in the New England Journal of Medicine was still ongoing, but they said two-thirds of …

State of Texas

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | Yahoo News | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

State of California

COVID-19 Treatments — Coronavirus Today | 6/30/2020

… immune modulator for the treatment of outpatients with early COVID-19 disease. June 26, 2020 - The governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $750,000 to Dr. Xiaokui Zhang at Celularity to … to standard treatment did not significantly improve the time to clinical improvement within 28 days, although the trial was terminated early and may have been underpowered to detect a clinically important difference, reported a study …

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | Yahoo News | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

State of Florida

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | Yahoo News | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

Chicago, Illinois

More positive results for antiviral drug remdesivir in battle against COVID-19 | Chicago Tribune | 6/3/2020

Chicago Tribune Jun 02, 2020 6:57 PM Dr. Gregory Huhn, an infectious disease physician at Stroger Hospital, poses for a portrait on May 4, 2020, outside of Cook County Health in Chicago. Huhn headed up … this newsletter. See all newsletters. “Now with solid evidence of clinical improvement for both severe illness and moderate illness … I would believe that these data would move the FDA for licensure consideration,” Huhn said. The …

Live updates on COVID-19: April 1-15 | Modern Healthcare | 5/5/2020

… 8:45 PM CT on 4/10/2020 A compassionate-use trial of remdesivir on patients hospitalized for severe COVID-19 resulted in clinical improvement 36 of 53, or 68%, of patients, according to an article in the … not near leveling off 4:49 PM CT on 4/10/2020 ( Crain’s Chicago Business ) If Italy’s COVID journey is any indication of the path we’re taking, then we’re starting to see the light at the end of …

Boston, Massachusetts

Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation | 6/22/2020

… Amyloid Angiopathy–Related Inflammation 1 J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston 2 Neuropathology Service, C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Harvard Medical … of 48 patients with cerebral amyloid angiopathy–related inflammation, both clinical improvement and radiographic improvement were more likely to occur in individuals treated with an immunosuppressive agent than in untreated individuals; recurrence was also significantly …

726 IMPACT OF LUMEN-APPOSING METAL STENTS ON THE LONG-TERM MANAGEMENT OF DISCONNECTED PANCREATIC DUCT SYNDROME | 6/1/2020

Boston Scientific, USA). After confirmation of clinical improvement and resolution of the fluid collection on follow-up CT/MRI at 3 to 4 weeks, the LAMS were removed. In patients with DPDS, when feasible, the LAMS were replaced with 7Fr double pigtail plastic stents to facilitate the drainage of the disconnected pancreatic segment and to prevent PFC recurrence. All patients were prospectively followed for a minimum duration of 6 months …